Physician profile
Samuel E Myrick
NPI 1831180546
$30,109.61
in general payments reported to CMS, 2019-2025
92 companies · $4,616 in 2025
The $4,616 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $4,082 · 2020: $2,443 · 2021: $3,612 · 2022: $4,349 · 2023: $4,411 · 2024: $6,597 · 2025: $4,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Long Term Medical Supply Or Device Loan: $1,180 · Education: $956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,488.26 |
| Long Term Medical Supply Or Device Loan | $1,180.03 |
| Education | $955.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,760.39 | 2019-2025 | |
| Pfizer INC. | $1,691.79 | 2019-2025 | |
| Janssen Biotech, INC. | $1,668.24 | 2019-2025 | Erleada, Rybrevant, Imbruvica |
| Astrazeneca Pharmaceuticals LP | $1,617.51 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Merck Sharp & Dohme LLC | $1,360.13 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $1,165.11 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Astellas Pharma US INC | $1,064.23 | 2019-2025 | Padcev, Xtandi, Vyloy |
| Amgen INC. | $1,052.46 | 2019-2024 | Lumakras, Kyprolis, Nplate |
| Seagen INC. | $981.61 | 2019-2025 | Tukysa, Adcetris, Tivdak |
| E.R. Squibb & Sons, L.L.C. | $942.71 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Incyte Corporation | $794.59 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Daiichi Sankyo INC. | $711.84 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Glaxosmithkline, LLC. | $675.39 | 2019-2025 | Ojjaara, Jemperli, Zejula |
| Bayer Healthcare Pharmaceuticals INC. | $661.81 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $584.11 | 2019-2025 | Zepzelca |
Show all 91 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $565.46 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Genzyme Corporation | $557.18 | 2019-2025 | |
| Eisai INC. | $551.03 | 2019-2025 | |
| Genmab U.S., INC. | $534.19 | 2023-2025 | Epkinly |
| Genentech USA, INC. | $528.34 | 2019-2025 | Venclexta, Polivy, Tecentriq |
| Regeneron Healthcare Solutions, INC. | $514.15 | 2019-2025 | Libtayo, Lynozyfic |
| Takeda Pharmaceuticals U.S.A., INC. | $457.19 | 2019-2025 | Fruzaqla, Alunbrig, Iclusig |
| Pharmacyclics LLC, An Abbvie Company | $450.16 | 2019-2023 | Imbruvica |
| Emd Serono, INC. | $430.47 | 2019-2025 | Bavencio |
| Kite Pharma, INC. | $379.34 | 2020-2023 | Yescarta |
| Ipsen Biopharmaceuticals, INC | $369.26 | 2019-2025 | Onivyde, Somatuline Depot |
| Servier Pharmaceuticals LLC | $363.06 | 2021-2025 | |
| Puma Biotechnology, INC. | $332.61 | 2019-2025 | |
| Gilead Sciences, INC. | $313.36 | 2021-2025 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $296.71 | 2019-2024 | Rezlidhia, Tavalisse |
| Octapharma USA, INC. | $294.97 | 2021-2023 | Panzyga, Octagam Immune Globulin (Human) |
| Array Biopharma INC | $281.79 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
| Abbvie INC. | $225.97 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.41 | 2019-2025 | Gilotrif |
| Karyopharm Therapeutics INC. | $191.24 | 2020-2023 | Xpovio |
| Novocure INC. | $185.41 | 2024-2025 | Optune Lua (Novottf-200t), Optune Gio |
| Janssen Scientific Affairs, LLC | $183.09 | 2019-2022 | |
| Stemline Therapeutics INC. | $176.09 | 2023-2025 | Orserdu |
| Alexion Pharmaceuticals, INC. | $175.54 | 2019-2025 | Ultomiris |
| Pharmaessentia USA Corporation | $168.72 | 2022-2025 | Besremi |
| Mirati Therapeutics, INC. | $164.00 | 2023-2024 | Krazati |
| Tersera Therapeutics LLC | $154.46 | 2019-2025 | Quzyttir, Zoladex |
| Taiho Oncology, INC. | $149.77 | 2019-2025 | |
| G1 Therapeutics, INC. | $136.94 | 2022-2023 | Cosela |
| Caris Mpi, INC. | $130.89 | 2025 | Mi Cancer Seek |
| Beigene USA, INC. | $130.66 | 2020-2024 | Brukinsa |
| Fennec Pharmaceuticals, INC. | $129.59 | 2024-2025 | Fyarro, Pedmark |
| Dendreon Pharmaceuticals LLC | $128.28 | 2024-2025 | Provenge |
| Pharmacosmos Therapeutics INC. | $126.58 | 2022-2024 | Cosela |
| Dova Pharmaceuticals | $126.03 | 2020-2021 | |
| Agios Pharmaceuticals, INC. | $123.04 | 2019-2025 | Pyrukynd |
| Morphosys, US INC. | $117.43 | 2021-2023 | Monjuvi |
| Foundation Medicine, INC. | $116.86 | 2020-2021 | |
| Clovis Oncology, INC. | $115.72 | 2019 | |
| Aveo Pharmaceuticals, INC. | $105.35 | 2021-2025 | |
| Menarini Silicon Biosystems, INC. | $102.00 | 2025 | |
| Cti Biopharma Corp. | $97.32 | 2022-2023 | Vonjo |
| Deciphera Pharmaceuticals INC. | $92.49 | 2021-2025 | Qinlock, Romvimza |
| Sun Pharmaceutical Industries INC. | $88.05 | 2020-2025 | |
| Tg Therapeutics, INC. | $87.39 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $83.03 | 2022-2024 | Empaveli |
| Exelixis INC. | $73.85 | 2019-2025 | Cabometyx |
| Geron Corporation | $72.80 | 2024-2025 | Rytelo |
| Tesaro, INC. | $70.02 | 2019 | |
| Immunocore Limited | $65.37 | 2023-2025 | Kimmtrak |
| Heron Therapeutics, INC. | $64.79 | 2021-2022 | |
| Csl Behring | $62.91 | 2021-2024 | Afstyla, Idelvion |
| Sobi, INC | $60.45 | 2023-2024 | |
| Adc Therapeutics America, INC. | $56.66 | 2023 | |
| Legend Biotech USA INC. | $56.02 | 2025 | Carvykti |
| Epizyme, INC. | $52.48 | 2020-2022 | |
| Secura Bio, INC. | $49.29 | 2019-2025 | Copiktra |
| Blueprint Medicines Corporation | $48.40 | 2021-2024 | Ayvakit |
| Astellas Pharma Global Development | $48.30 | 2019 | |
| Global Blood Therapeutics, INC. | $48.00 | 2020-2022 | |
| Kyowa Kirin, INC. | $33.32 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $29.95 | 2020 | |
| Coherus Oncology, INC. | $27.38 | 2024-2025 | Loqtorzi |
| Tempus Ai, INC | $23.25 | 2024 | Xt Cdx |
| Springworks Therapeutics, INC. | $22.21 | 2025 | Ogsiveo |
| Acrotech Biopharma INC. | $19.92 | 2023 | Beleodaq |
| Medtronic, INC. | $19.58 | 2022 | |
| Advanced Accelerator Applications | $18.98 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $18.69 | 2019 | |
| Adaptive Biotechnologies Corporation | $18.46 | 2025 | Clonoseq |
| Tolmar Pharmaceuticals, INC. | $18.17 | 2021 | |
| Emmaus Medical, INC. | $17.13 | 2022 | |
| Alnylam Pharmaceuticals INC. | $16.69 | 2021 | |
| Grifols USA, LLC | $15.95 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $12.69 | 2019 | |
| Ge Healthcare | $10.36 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3,965.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Myrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.